Skip to navigation Skip to content



University College London Receives National MS Society Funding to Identify and Refine Nerve-Protecting Therapies

January 14, 2016

Researchers at the University College London and Queen Mary University (London, U.K.) have developed possible neuroprotective therapies for the treatment of neurodegenerative diseases including multiple sclerosis. With previous National MS Society funding through Fast Forward, the team produced a compound (JW47) that was effective in a mouse model of MS. The compound targets mitochondria, the power plants inside cells whose malfunction can lead to nerve cell loss. The collaborators have received new funding from Fast Forward to refine this and other compounds to optimize their potential use in stopping or slowing progressive MS.

Read more about this research
Read more about the Society’s commercial research investments
Read more about research to find solutions to progressive MS

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.